[ad_1]
People with a history of “major” allergic reactions have been advised not to currently receive Pfizer / BioNTech. COVID-19 vaccine after two people who received the injection Tuesday had allergic reactions.
Two NHS staff members who were hit on the first day of the mass vaccination program suffered an allergic reaction, England’s NHS has confirmed.
Both are recovering, it is understood.
The NHS in England said that all trusts involved with the vaccination program have been informed.
It is understood that both staff members had a significant history of allergic reactions, to the extent that they need to carry an adrenaline auto-injector.
They developed symptoms of an “anaphylactoid reaction” shortly after receiving the vaccine and both recovered after appropriate treatment.
The Medicines and Healthcare Products Regulatory Agency (MHRA) has given precautionary advice to the NHS and is confident that anyone with a history of “significant” allergic reactions to drugs, foods or vaccines should not receive the vaccine. .
Professor Stephen Powis, National Medical Director of the NHS in England, said: “As is common with new vaccines, the MHRA has advised as a precaution that people with a significant history of allergic reactions do not receive this vaccine after two people with a history of allergic reactions of significant allergic reactions responded negatively yesterday. They are both recovering well. ”
The MHRA advice states: “Anyone with a history of a significant allergic reaction to a vaccine, drug or food (such as a prior history of anaphylactoid reaction or those who have been recommended to carry an adrenaline autoinjector) should not receive the Pfizer / BioNtech vaccine.
“Resuscitation facilities must be available at all times for all vaccines. Vaccination should only be carried out in facilities where resuscitation measures are available.”
The Executive Director of the Medicines and Health Products Regulatory Agency (MHRA), Dr. June Raine, said that careful plans had been made for “real-time surveillance” when monitoring the side effects of vaccines and that any updates to advice for patients would be communicated “immediately”.
Appearing at the Commons Science and Technology Committee on Wednesday, he said regulators were aware that two people who had received the vaccine had experienced allergic reactions.
“The role is before, during and after, and there is a real look from start to finish from the scientific laboratory to the patient who received the vaccine for the first time yesterday,” he said.
“As an illustration of this, I can share with the committee that even last night we were looking at two case reports of allergic reactions.
“We know from very large clinical trials that this was not a feature, but if we need to strengthen our advice now that we have had this experience in vulnerable populations … we will send that advice to the field immediately.”
